Navigation Links
Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
Date:6/16/2011

d pain will also be presented in two distinct poster sessions:

  • "Elagolix, A Novel Oral GnRH Antagonist Improves Quality Of Life In Women With Endometriosis-Associated Pelvic Pain" on Tuesday, September 6, 2011 at 8:00 am
  • "Elagolix, A Novel Oral GnRH Antagonist, Maintained Reduction Of Endometriosis-Associated Pelvic Pain During 24 Weeks Of Treatment" on Wednesday, September 7, 2011 at 8:00 am

In addition, data from the extensive work undertaken to improve our understanding of endometriosis symptoms will be presented at the 11th World Congress on Endometriosis in two separate sessions:

  • "A Qualitative Evaluation of Disease Severity and Bothersomeness of Symptoms In Patients with Endometriosis" on Tuesday, September 6, 2011 at 8:00 am
  • "Perception of Pelvic Pain in Women with Endometriosis: A Focus Group Study" on Wednesday, September 7, 2011 at 11:30 am.  

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, and Company overall. In addition, the Company faces
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Click here for additional information on ... DPLO ), the nation,s largest independent specialty pharmacy, ... 31, 2014. All comparisons, unless otherwise noted, are to the ... Fourth Quarter 2014 Highlights include: , Revenue of ... dispensed of 208,000, an increase of 11% , Gross ...
(Date:3/2/2015)... , March 2, 2015  Vivex Biomedical, Inc., a ... and biocellular products, announced today that it hired ... of UMTB Biomedical, Inc.   Vivex Biomedical formed UMTB Biomedical ... Miami Tissue Bank (UMTB) in November 2014. UMTB is ... Mr. Barnes is a twenty-five year veteran of the ...
(Date:3/2/2015)... March 2, 2015  Champions Oncology, Inc. (OTC-PINK: CSBR), ... solutions and services to personalize the development and use ... on the $2 million convertible promissory notes with two ... Dr. David Sidransky , chairman ... benefit from the confidence and commitment of our two ...
Breaking Medicine Technology:Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 2Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 3Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 4Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 6Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 7Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 8Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 9Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 10Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 11Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 13Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 14Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 15Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 16Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 17Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 18Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 19Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 20Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 21Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3Champions Oncology Extends Convertible Debt Financing 2Champions Oncology Extends Convertible Debt Financing 3
(Date:3/2/2015)... March 02, 2015 “ Wants and ... its monthly AppWatch, which features the latest and coolest ... Andrew Tropeano, a mobile technology expert and host of ... how this app helps people evaluate priorities. , Whether ... the Wants and Needs app. The app allows people ...
(Date:3/2/2015)... Raleigh, NC (PRWEB) March 02, 2015 ... response can be a better predictor of outcomes for ... here to read details of the new study ... and pathologists at the University of Eastern Piedmont followed ... underwent talc pleurodesis treatment for excess lung fluid. ...
(Date:3/2/2015)... Alabama (PRWEB) March 02, 2015 Robins ... - In conjunction with Women in Construction Week (March ... Construction, or NAWIC) and National Women’s History Month, Robins ... commitment positively affect the company and the construction industry ... management team, to the dozens of roles in between, ...
(Date:3/2/2015)... York (PRWEB) March 02, 2015 ... at Recovery Unplugged™—will be delivering a plenary address ... Perspective on the Art of Healing and Recovery ... (NCAD) and Behavioral Healthcare Executive Summit (BHES).     , ... Mr. Supa’s songs have been recorded by some ...
(Date:3/2/2015)... Mountain View, CA (PRWEB) March 02, 2015 ... announced today that it has officially launched a ... Bo Gustafsson, head of product development for BNatrl, ... developed through feedback from Olympic and other world-class ... I'm excited to use this pure whole food ...
Breaking Medicine News(10 mins):Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Robins & Morton Recognizes Women In Construction 2Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Bnatrl Launches Multivitamin Supplement for Runners 2
... Start-up FundingMINNEAPOLIS, May 4 CoreSpine Technologies, a ... received 510(k) clearance to market from the U.S. ... Nucleus Removal System. "The clearance of the ... CoreSpine," said Christine Horton, Chief Executive Officer of ...
... wellness & HR summit for organizations in SE ... decision makers and HR professionals. Increase wellness, decrease ... productivity. TROY, Mich., May 4 Cambridge Employee ... host its fourth annual corporate Wellness & HR ...
... Group, a life science-focused strategic communications agency, announced today ... sciences agency client roster.Donna L. LaVoie, President & CEO ... working on the leading edge of the life sciences ... therapeutics for complex central nervous system disorders, Mithridion,s strategy ...
... Information from American Red CrossCHICAGO, May 4 As ... to the swine flu (H1N1 flu outbreak), millions of ... caregiver options. In response to this recent flu ... to Sittercity.com for the month of May. With ...
... members and 18 foreign associates from 15 countries elected recently to the ... ... CA (Vocus) May 4, 2009 -- Five UCSF faculty scientists ... countries elected recently to the National Academy of Sciences, the Academy has ...
... attention to urgency in preventing stroke and supporting 6 million stroke survivors ... ... year nearly 795,000 people will have a stroke, leaving a path of ... National Stroke Association , which is observing National Stroke Awareness Month ...
Cached Medicine News:Health News:CoreSpine Technologies(TM) Receives Clearance to Market Surgical Disc Preparation Device 2Health News:Cambridge Employee Benefits to Host Corporate Wellness & HR Summit 2Health News:LaVoie Group Appointed by Mithridion as PR Agency 2Health News:In-Home Caregivers Standing by Nationwide to Support Increased Need Due to Swine Flu 2Health News:Five UCSF Scientists Elected to National Academy of Sciences 2Health News:Five UCSF Scientists Elected to National Academy of Sciences 3Health News:Five UCSF Scientists Elected to National Academy of Sciences 4Health News:Five UCSF Scientists Elected to National Academy of Sciences 5Health News:Five UCSF Scientists Elected to National Academy of Sciences 6Health News:Five UCSF Scientists Elected to National Academy of Sciences 7Health News:Five UCSF Scientists Elected to National Academy of Sciences 8Health News:Four of Five Families Will Be Touched by Stroke in 2009 2
Inquire...
Inquire...
... Power Assisted Lipoplasty Device uses a 2-mm reciprocating ... the movement of the cannula in tissue. So ... more fibrous tissue. That makes the lipoplasty procedure ... ease your mind to learn that the PAL® ...
... level. Incredibly quiet, yet very powerful. Attachment ... at one time eliminates the need to ... canister set-up is for Abbott 2000ml system ... and CE marks. Includes a wireless foot-switch. ...
Medicine Products: